DMAC
NASDAQ · Biotechnology
Diamedica Therapeutics Inc
$7.29
+0.53 (+7.84%)
Financial Highlights (FY 2025)
Revenue
75.08M
Net Income
7.50M
Gross Margin
29.0%
Profit Margin
10.0%
Rev Growth
+22.4%
D/E Ratio
0.48
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 29.0% | 29.0% | 29.0% |
| Operating Margin | 12.6% | 12.1% | 10.3% |
| Profit Margin | 10.0% | 8.9% | 8.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 75.08M | 73.96M | 78.61M |
| Gross Profit | 21.74M | 21.42M | 22.77M |
| Operating Income | 9.42M | 8.93M | 8.11M |
| Net Income | 7.50M | 6.55M | 6.83M |
| Gross Margin | 29.0% | 29.0% | 29.0% |
| Operating Margin | 12.6% | 12.1% | 10.3% |
| Profit Margin | 10.0% | 8.9% | 8.7% |
| Rev Growth | +22.4% | +12.6% | +21.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 160.62M | 170.83M | 154.73M |
| Total Equity | 335.74M | 362.05M | 333.03M |
| D/E Ratio | 0.48 | 0.47 | 0.46 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 9.74M | 10.19M | 9.65M |
| Free Cash Flow | 6.22M | 6.24M | 10.05M |